← Back to patent-cliff list
Selvigaltin
Tier C — Watch / tradeSelvigaltin
Galecto Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：Gal-3
Indications (approved)：Melanoma, Head and neck squamous cell carcinoma, Non-small cell lung cancer, Hepatic function decline, Multiple myeloma, Non-alcoholic steatohepatitis
Regional status
US
Phase II
2024-02-29
EU
Phase II
2021-09-09
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Selvigaltin?
Approved indications include: Melanoma, Head and neck squamous cell carcinoma, Non-small cell lung cancer, Hepatic function decline, Multiple myeloma, Non-alcoholic steatohepatitis.
When does the Selvigaltin patent expire?
No public expiry year is available for Selvigaltin yet; this page updates once verified.
How do I get a quote for Selvigaltin intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-06